KR100551510B1 - 활성 물질 및 시클로덱스트린을 포함하는 경구 투여용약제 조성물 - Google Patents

활성 물질 및 시클로덱스트린을 포함하는 경구 투여용약제 조성물 Download PDF

Info

Publication number
KR100551510B1
KR100551510B1 KR1019997012573A KR19997012573A KR100551510B1 KR 100551510 B1 KR100551510 B1 KR 100551510B1 KR 1019997012573 A KR1019997012573 A KR 1019997012573A KR 19997012573 A KR19997012573 A KR 19997012573A KR 100551510 B1 KR100551510 B1 KR 100551510B1
Authority
KR
South Korea
Prior art keywords
cyclodextrin
cetirizine
active substance
pharmaceutical composition
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019997012573A
Other languages
English (en)
Korean (ko)
Other versions
KR20010014398A (ko
Inventor
도메니코 파나라
모니크 베르와어
필리페 놀프
헨리 브랑큭스
미셸 델리어스
Original Assignee
유씨비 소시에떼아노님
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3890611&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100551510(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 유씨비 소시에떼아노님 filed Critical 유씨비 소시에떼아노님
Publication of KR20010014398A publication Critical patent/KR20010014398A/ko
Application granted granted Critical
Publication of KR100551510B1 publication Critical patent/KR100551510B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Nutrition Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1019997012573A 1997-07-03 1998-07-02 활성 물질 및 시클로덱스트린을 포함하는 경구 투여용약제 조성물 Expired - Fee Related KR100551510B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BE9700572A BE1011251A3 (fr) 1997-07-03 1997-07-03 Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
BE9700572 1997-07-03
PCT/BE1998/000100 WO1999001133A1 (fr) 1997-07-03 1998-07-02 Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine

Publications (2)

Publication Number Publication Date
KR20010014398A KR20010014398A (ko) 2001-02-26
KR100551510B1 true KR100551510B1 (ko) 2006-02-13

Family

ID=3890611

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019997012573A Expired - Fee Related KR100551510B1 (ko) 1997-07-03 1998-07-02 활성 물질 및 시클로덱스트린을 포함하는 경구 투여용약제 조성물

Country Status (20)

Country Link
US (1) US6455533B1 (enExample)
EP (1) EP0994710B2 (enExample)
JP (2) JP2002508773A (enExample)
KR (1) KR100551510B1 (enExample)
CN (1) CN1150900C (enExample)
AT (1) ATE224717T1 (enExample)
AU (1) AU727140B2 (enExample)
BE (1) BE1011251A3 (enExample)
BR (1) BR9810495A (enExample)
CA (1) CA2294783C (enExample)
DE (1) DE69808297T3 (enExample)
DK (1) DK0994710T4 (enExample)
ES (1) ES2184293T5 (enExample)
ID (1) ID23806A (enExample)
IL (1) IL133397A (enExample)
NZ (1) NZ501820A (enExample)
PL (1) PL192348B1 (enExample)
PT (1) PT994710E (enExample)
RU (1) RU2192863C2 (enExample)
WO (1) WO1999001133A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0028575D0 (en) * 2000-11-23 2001-01-10 Elan Corp Plc Oral pharmaceutical compositions containing cyclodextrins
US20040213839A1 (en) * 2001-02-05 2004-10-28 Andrew Favara Methods and compositions for reducing the taste of pharmaceutically active agents
NZ534039A (en) * 2002-01-15 2006-08-31 Ucb Farchim S Formulations of pharmaceutical compositions for oral administration
PL372904A1 (en) * 2002-04-04 2005-08-08 Pfizer Products Inc. Palatable chewable tablet
CA2574602A1 (en) * 2004-07-22 2006-02-02 Pfizer Products Inc. Taste masking formulation comprising the drug in a dissolution-retarded form and/or cyclodextrin in a dissolution-enhanced form
US20060147518A1 (en) * 2004-12-30 2006-07-06 Pierre Fabre Medicament Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it
US20060198885A1 (en) * 2005-02-22 2006-09-07 Sun Pharmaceutical Industries Ltd. Oral pharmaceutical composition
US20070086974A1 (en) * 2005-10-06 2007-04-19 Gawande Rahul S Cetirizine compositions
US20090269393A1 (en) * 2006-06-12 2009-10-29 Jubliant Organosys Limited Chewable Bilayer Tablet Formulation
JP2008143807A (ja) * 2006-12-07 2008-06-26 Sato Pharmaceutical Co Ltd 感冒薬カプセル剤及びその製造方法
EP2550967A1 (en) * 2007-07-11 2013-01-30 Fertin Pharma A/S Compressed chewing gum tablet comprising taste-masking agent
US20100260818A1 (en) * 2007-07-11 2010-10-14 Fertin Pharma A/S Stable medicated chewing gum comprising cyclodextrin inclusion complex
WO2009054432A1 (ja) * 2007-10-26 2009-04-30 Daiichi Sankyo Company, Limited 口腔内速崩壊性医薬組成物およびその製造方法
US8138192B2 (en) * 2007-10-31 2012-03-20 Genebiology, Inc. Injectable meclizine formulations and methods
WO2009061465A1 (en) * 2007-11-06 2009-05-14 Teva Pharmaceutical Industries Ltd. Chewable formulations
ES2564056T3 (es) * 2008-09-05 2016-03-17 Johnson & Johnson Consumer Inc. Método para hacer pastillas de cetirizina
WO2011110939A2 (en) 2010-03-11 2011-09-15 Rubicon Research Private Limited Pharmaceutical compositions of substituted benzhydrylpiperazines
WO2011150859A1 (en) * 2010-06-04 2011-12-08 Comprehensive Drug Enterprises Ltd Oral meclizine aqueous formulations with taste flavoring agent
CN101905027A (zh) * 2010-07-27 2010-12-08 北京华禧联合科技发展有限公司 含米格列奈钙和环糊精的口服药用组合物
AU2011302293B2 (en) 2010-09-13 2015-11-26 Bev-Rx, Inc. Aqueous drug delivery system comprising off - flavor masking agent
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
RU2589833C2 (ru) * 2013-12-12 2016-07-10 Общество С Ограниченной Ответственностью "Фарма Старт" Твердая лекарственная форма препарата седативного и снотворного действия
DK3122330T3 (en) * 2014-03-27 2018-10-22 Ucb Farchim Sa Pharmaceutical compositions comprising levocetirizine
IL302218B2 (en) 2014-08-28 2024-10-01 Eisai R&D Man Co Ltd Methods for manufacturing high-purity lenvatinib and its derivatives
JP6792546B2 (ja) 2015-02-25 2020-11-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体の苦味抑制方法
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
EP3311841B1 (en) 2015-06-16 2021-07-28 PRISM BioLab Co., Ltd. Anticancer agent
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
RU2750539C2 (ru) 2017-02-08 2021-06-29 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Фармацевтическая композиция для лечения опухоли
AU2018269996A1 (en) 2017-05-16 2019-11-21 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
KR102110304B1 (ko) * 2017-06-30 2020-05-14 한미약품 주식회사 레보세티리진 및 몬테루카스트를 포함하는 안정성 및 복약순응도가 향상된 복합 츄어블정 및 그 제조방법
EP4099977A1 (en) * 2020-02-03 2022-12-14 Johnson & Johnson Consumer Inc. A single layer chewable tablet comprising cetirizine
WO2022106923A1 (en) 2020-11-18 2022-05-27 BioPharma Synergies, S. L. Orodispersible powder composition comprising an antihistamine compound

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525358A (en) * 1981-02-06 1985-06-25 Ucb Pharmaceuticals, Inc. 2-[4-(Diphenylmethyl)-1-piperazinyl]-acetic acids and their amides
US5206025A (en) * 1989-05-24 1993-04-27 Rhone-Poulenc Sante Porous pharmaceutical form and its preparation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58177949A (ja) * 1982-04-12 1983-10-18 Takeda Chem Ind Ltd ランカシジン群抗生物質包接化合物
JPS60204712A (ja) * 1984-03-29 1985-10-16 Ss Pharmaceut Co Ltd 塩酸メクリジンの安定化液状組成物
JPS63243031A (ja) † 1987-03-28 1988-10-07 Tokyo Tanabe Co Ltd 胆汁酸の固形製剤
FR2647343B1 (fr) * 1989-05-24 1994-05-06 Rhone Poulenc Sante Nouvelle forme pharmaceutique poreuse et sa preparation
CA2145410A1 (en) † 1992-09-24 1994-03-31 Nancy M. Gray Compositions for treating allergic disorders using (-) cetirizine
TW401300B (en) * 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
ES2166811T3 (es) * 1993-12-01 2002-05-01 Byk Gulden Lomberg Chem Fab Amino-alquil-amino-piridinas sustituidas.
US5866179A (en) 1996-05-03 1999-02-02 Avant-Garde Technologies & Products S.A. Medicated chewing gum and a process for preparation thereof
GB0028575D0 (en) * 2000-11-23 2001-01-10 Elan Corp Plc Oral pharmaceutical compositions containing cyclodextrins
CA2574602A1 (en) * 2004-07-22 2006-02-02 Pfizer Products Inc. Taste masking formulation comprising the drug in a dissolution-retarded form and/or cyclodextrin in a dissolution-enhanced form

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525358A (en) * 1981-02-06 1985-06-25 Ucb Pharmaceuticals, Inc. 2-[4-(Diphenylmethyl)-1-piperazinyl]-acetic acids and their amides
US5206025A (en) * 1989-05-24 1993-04-27 Rhone-Poulenc Sante Porous pharmaceutical form and its preparation

Also Published As

Publication number Publication date
DE69808297D1 (de) 2002-10-31
AU727140B2 (en) 2000-12-07
PT994710E (pt) 2003-02-28
NZ501820A (en) 2000-10-27
CA2294783A1 (fr) 1999-01-14
EP0994710A1 (fr) 2000-04-26
US20020032217A1 (en) 2002-03-14
JP2002508773A (ja) 2002-03-19
ES2184293T5 (es) 2006-01-16
DK0994710T4 (da) 2005-10-17
JP2007091760A (ja) 2007-04-12
PL337794A1 (en) 2000-09-11
ID23806A (id) 2000-05-11
DE69808297T3 (de) 2006-01-19
AU8201598A (en) 1999-01-25
US6455533B1 (en) 2002-09-24
CN1261799A (zh) 2000-08-02
KR20010014398A (ko) 2001-02-26
DK0994710T3 (da) 2003-01-20
EP0994710B1 (fr) 2002-09-25
IL133397A0 (en) 2001-04-30
PL192348B1 (pl) 2006-10-31
BE1011251A3 (fr) 1999-06-01
CN1150900C (zh) 2004-05-26
BR9810495A (pt) 2000-09-12
WO1999001133A1 (fr) 1999-01-14
ES2184293T3 (es) 2003-04-01
IL133397A (en) 2005-07-25
CA2294783C (fr) 2006-11-14
RU2192863C2 (ru) 2002-11-20
EP0994710B2 (fr) 2005-09-21
ATE224717T1 (de) 2002-10-15
DE69808297T2 (de) 2003-04-17
HK1029060A1 (en) 2001-03-23

Similar Documents

Publication Publication Date Title
KR100551510B1 (ko) 활성 물질 및 시클로덱스트린을 포함하는 경구 투여용약제 조성물
JP5467685B2 (ja) 処方
RU2118899C1 (ru) Пероральные противогрибковые композиции
EP1494654B1 (en) Palatable chewable tablet
CA2254434A1 (en) Droloxifene pharmaceutical compositions
MXPA99011899A (en) Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin
Becirevic Brussels (BE); Michel Deleers, Linkebeek (BE) FOREIGN PATENT DOCUMENTS
HK1029060B (en) Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin
Mahapatra et al. Solubility enhancement of etoricoxib using inclusion complexation with cyclodextrins: formulation of oro dispersible tablets by QbD approach
AU2003209953B2 (en) Palatable chewable tablet
EP4561542A1 (en) Orally disintegrating palatable formulations of drotaverine and method of preparation thereof
CZ145696A3 (en) Estramustine formulations exhibiting improved pharmaceutical properties
Zalaki Formulation and Evaluation of Ternary System for Solubility Enhancement of a Second Generation Cox-II Inhibitior
MXPA98009888A (en) Pharmaceutical compositions of droloxif
HUP0100028A2 (en) Oral pharmaceutical compositions containing sildenafil with cyclodextrins

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20130117

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 20140120

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20150207

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20150207